细胞疗法製造市场规模、份额和成长分析（按治疗方法、细胞来源、营运规模和地区划分）—2026-2033年产业预测

预计到 2024 年，全球细胞疗法製造市场规模将达到 56.8 亿美元，到 2025 年将达到 68.4 亿美元，到 2033 年将达到 302.1 亿美元，预测期（2026-2033 年）的复合年增长率为 20.4%。

细胞疗法需求的不断增长推动了生产製造领域的创新，重点在于自动化、封闭式生物反应器和先进分析技术，以确保产品的一致性和符合监管要求。商业化生产设施的激增反映了这一趋势，尤其是在关键地区，成长尤为显着。然而，这种快速扩张也引发了人们对资料隐私、监管合规和品管的严重担忧。报告指出，针对细胞疗法公司的网路攻击频传，凸显了采取强而有力的资料保护措施的必要性。此外，生产流程的日益复杂化导致召回和监管警告的增加，凸显了在产业快速发展过程中，如何持续维护品质和病人安全所面临的挑战。

全球细胞疗法生产市场按疗法类型、细胞来源、业务规模和地区进行细分。依疗法类型划分，可分为T细胞疗法、干细胞疗法和树突细胞疗法。依细胞来源划分，可分为自体细胞、异体细胞及未明确来源细胞。依业务规模划分，可分为临床规模和商业规模。按地区划分，分析涵盖北美、欧洲、亚太地区、拉丁美洲以及中东和非洲。

全球细胞疗法製造市场驱动因素

癌症和自体免疫免疫疾病等慢性病发病率的上升显着推动了细胞疗法生产的需求。每年数百万新增癌症病例促使人们需要CAR-T细胞疗法和干细胞疗法等先进疗法。这种不断增长的需求刺激了对先进生产技术和可扩展製造解决方案的投资，使生物技术公司能够有效地满足尚未满足的医疗需求。因此，市场准入正在显着改善，尤其是在肿瘤学和再生医学领域，因为各公司都在寻求创新并适应不断变化的医疗保健格局。

全球细胞疗法製造市场面临的限制因素

全球细胞疗法生产市场面临许多限制因素，主要源自于生产流程的复杂性和高成本。诸如CAR-T疗法等个人化疗法需要精密的设备和专业的医护人员，这往往导致每位患者的治疗费用非常高。高成本限制了患者的可及性，尤其是在低收入社区，并阻碍了扩充性。此外，细胞品质不稳定和生产週期长等挑战也增加了生产的复杂性。这些因素共同阻碍了市场的建立和发展，为扩大治疗覆盖率和提高治疗效率设置了难以克服的障碍。

全球细胞疗法製造市场趋势

在全球细胞治疗生产市场，采用封闭式系统和自动化技术已成为一个显着趋势，显着提高了营运效率和扩充性。透过利用机器人系统和生物反应器，製造商减少了人为干预，降低了污染风险，并确保符合良好生产规范 (GMP)。一次性生物反应器的应用增强了无菌性，最大限度地降低了成本，并加快了生产週期。这对于同种异体移植疗法尤其有利，使其能够满足北美和亚太等关键地区（尤其是在肿瘤学和再生医学领域）日益增长的细胞治疗需求。

目录

介绍

• 调查目标
• 调查范围
• 定义

调查方法

• 资讯收集
• 二手资料和一手资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分市场机会分析

市场动态与展望

• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特分析

关键市场考察

• 关键成功因素
• 竞争程度
• 关键投资机会
• 市场生态系统
• 市场吸引力指数（2025）
• PESTEL 分析
• 总体经济指标
• 价值链分析
• 定价分析
• 技术分析
• 案例研究
• 顾客购买行为分析

全球细胞疗法製造市场规模（依治疗方法划分）及复合年增长率（2026-2033 年）

• T细胞疗法
• 干细胞疗法
• 树突细胞疗法

全球细胞疗法製造市场规模（按细胞来源和复合年增长率划分）（2026-2033 年）

• 自体
• 同种异体移植
• 未指定

全球细胞疗法製造市场规模（按企业规模和复合年增长率划分）（2026-2033 年）

• 临床
• 商业的

全球细胞疗法製造市场规模及复合年增长率（2026-2033）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 亚太其他地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业的市场定位（2025 年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市占率分析（2025 年）
• 主要企业公司简介
  • 公司详情
  • 产品系列分析
  • 依业务板块进行公司股票分析
  • 2023-2025年营收年比比较

主要企业简介

• AGC Biologics
• Charles River Laboratories
• FUJIFILM Cellular Dynamics
• Thermo Fisher Scientific
• WuXi AppTec
• Lonza
• Catalent
• BioNTech
• Cell and Gene Therapy Catapult
• Cell Therapies Pty Ltd
• Merck KGaA
• Takara Bio
• Bristol Myers Squibb
• Novartis

结论与建议

Global Cell Therapy Manufacturing Market size was valued at USD 5.68 Billion in 2024 and is poised to grow from USD 6.84 Billion in 2025 to USD 30.21 Billion by 2033, growing at a CAGR of 20.4% in the forecast period (2026-2033).

The escalating demand for cell therapy is driving innovation in manufacturing techniques, with a focus on automation, closed-system bioreactors, and advanced analytics to ensure product consistency and regulatory adherence. The proliferation of commercial manufacturing facilities reflects this trend, with significant growth observed in key regions. However, this rapid expansion has raised critical concerns regarding data privacy, regulatory compliance, and quality control. Reports indicate a notable incidence of cyberattacks targeting cell therapy firms, emphasizing the need for robust data protection measures. Additionally, the complexity of manufacturing processes has resulted in an uptick in recalls and regulatory warnings, highlighting the ongoing challenges in maintaining quality and patient safety amid the industry's rapid evolution.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Cell Therapy Manufacturing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Cell Therapy Manufacturing Market Segments Analysis

The global cell therapy manufacturing marketis segmented into therapy type, cell source, scale of operation, and region. By therapy type, the market is classified into T cell therapies, stem cell therapies, and dendritic cell therapies. Depending on the cell source, it is divided into autologous, allogeneic, and unspecified. According to scale of operation , the market is categorized into clinical and commercial. Regionally, it is analyzed across North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.

Driver of the Global Cell Therapy Manufacturing Market

The rising incidence of chronic conditions such as cancer and autoimmune disorders significantly fuels the demand for cell therapy manufacturing. With millions of new cancer diagnoses annually, the need for advanced treatments like CAR-T and stem cell therapies is on the rise. This growing demand propels investment in cutting-edge production technologies and scalable manufacturing solutions, allowing biotech firms to address unmet medical needs effectively. Consequently, there is a notable enhancement in market accessibility, particularly within the fields of oncology and regenerative medicine, as companies strive to innovate and meet the evolving healthcare landscape.

Restraints in the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market faces significant constraints due to the intricate and costly nature of the manufacturing process. Customized treatments, like CAR-T therapy, require advanced facilities and expert personnel, often exceeding substantial financial outlays per patient. Such high costs restrict access, especially in low-income regions, and hinder the potential for scalability. Moreover, challenges such as variability in cell quality and lengthy production timelines further contribute to the complexity of manufacturing. These factors collectively impede the establishment and growth of the market, creating obstacles that are difficult to navigate in expanding access and efficiency.

Market Trends of the Global Cell Therapy Manufacturing Market

The Global Cell Therapy Manufacturing market is witnessing a significant trend towards the implementation of closed system and automation technologies, enhancing operational efficiency and scalability. By leveraging robotic systems and bioreactors, manufacturers are reducing human interaction, thereby lowering the risk of contamination and ensuring compliance with Good Manufacturing Practices (GMP). The adoption of single-use bioreactors enhances sterility while minimizing costs and expediting production timelines. This is particularly advantageous for allogeneic therapies, allowing manufacturers to meet the rising demand for cell therapies across key regions such as North America and the Asia-Pacific, particularly in oncology and regenerative medicine sectors.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis
• Case Studies
• Customer Buying Behavior Analysis

Global Cell Therapy Manufacturing Market Size by Therapy Type & CAGR (2026-2033)

• Market Overview
• T cell therapies
• Stem cell therapies
• Dendritic cell therapies

Global Cell Therapy Manufacturing Market Size by Cell Source & CAGR (2026-2033)

• Market Overview
• Autologous
• Allogeneic
• Unspecified

Global Cell Therapy Manufacturing Market Size by Scale of Operation & CAGR (2026-2033)

• Market Overview
• Clinical
• Commercial

Global Cell Therapy Manufacturing Market Size & CAGR (2026-2033)

• North America (Therapy Type, Cell Source, Scale of Operation)
  • US
  • Canada
• Europe (Therapy Type, Cell Source, Scale of Operation)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Therapy Type, Cell Source, Scale of Operation)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Therapy Type, Cell Source, Scale of Operation)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Therapy Type, Cell Source, Scale of Operation)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• AGC Biologics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• FUJIFILM Cellular Dynamics
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Catalent
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell and Gene Therapy Catapult
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cell Therapies Pty Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takara Bio
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations